Chongqing University Cancer Hospital
cqch.orgTotal trials
43
Active
24
Phase 3
1
Total enrollment
22,657
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 17 of 17 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Ondansetron orodispersible film once | — | — | — | — | — | 1 | |
| Ondansetron orodispersible film twice | — | — | — | — | — | 1 | |
| metronomic adjuvant chemotherapy with capecitabine | — | — | — | — | — | 1 | |
| Camrelizumab | — | — | — | — | — | 2 | |
| Tislelizumab Combined With Chemotherapy | — | — | — | — | — | 1 | |
| Cadonilimab（AK104） | — | — | — | — | — | 1 | |
| Drug: Cisplatin | — | — | — | — | — | 1 | |
| Enlonstobart | — | — | — | — | — | 1 | |
| fluzopanib and bevacizumab | — | — | — | — | — | 1 | |
| Envafolimab | — | — | — | — | — | 1 | |
| Cisplatin | — | — | — | — | — | 1 | |
| Serplulimab | — | — | — | — | — | 1 | |
| Oncolytic Virus H101 | — | — | — | — | — | 1 | |
| XELOX Chemotherapy | — | — | — | — | — | 1 | |
| Fluzoparib monotherapy or Fluzoparib with Camrelizumab | — | — | — | — | — | 1 | |
| Envafolimab and recombinant human endostatin combined with chemoradiotherapy | — | — | — | — | — | 1 | |
| Paclitaxel, Cisplatin | — | — | — | — | — | 1 |
Next readouts
- 2024-04
- 2024-08-01
- 2024-08-30
- 2024-11-30
- 2024-12-30
- 2025-06-01
- 2026-03
- 2027-02-01
- 2027-05-31
- 2027-12-31
Top conditions
- Cervical Cancer8
- Locally Advanced Cervical Cancer6
- Ovarian Cancer5
- Nasopharyngeal Cancinoma (NPC)2
- Non-small Cell Lung Cancer2
- Nasopharyngeal Carcinoma2
- Extensive Stage Small Cell Lung Cancer (ES-SCLC)1
- Radiotherapy-induced Nausea and Vomiting (RINV)1
Frequently asked questions about Chongqing University Cancer Hospital
- How many clinical trials does Chongqing University Cancer Hospital have on ClinicalTrials.gov?
- Chongqing University Cancer Hospital is listed as the lead sponsor on 43 clinical trials in ClinicalTrials.gov, 24 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Chongqing University Cancer Hospital's trials are in Phase 3?
- 1 of Chongqing University Cancer Hospital's trials are in Phase 3, spread across 17 active drug programs.
- What therapeutic areas does Chongqing University Cancer Hospital focus on?
- Chongqing University Cancer Hospital's most-studied conditions on ClinicalTrials.gov are Cervical Cancer, Locally Advanced Cervical Cancer, Ovarian Cancer, Nasopharyngeal Cancinoma (NPC), Non-small Cell Lung Cancer.
- When are Chongqing University Cancer Hospital's next clinical trial readouts?
- Chongqing University Cancer Hospital has 10 upcoming primary-completion readouts tracked here; the soonest is “The Efficacy of Adjuvant Chemotherapy in Locally Advanced Cervical Cancer”, expected around 2024-04.